These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 8109985

  • 1. [Role of metallothionein in cancer chemotherapy].
    Naganuma A, Imura N.
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):301-6. PubMed ID: 8109985
    [Abstract] [Full Text] [Related]

  • 2. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis.
    Satoh M, Kloth DM, Kadhim SA, Chin JL, Naganuma A, Imura N, Cherian MG.
    Cancer Res; 1993 Apr 15; 53(8):1829-32. PubMed ID: 8467502
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.
    Kondo Y, Himeno S, Satoh M, Naganuma A, Nishimura T, Imura N.
    Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):33-8. PubMed ID: 14530870
    [Abstract] [Full Text] [Related]

  • 6. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice.
    Naganuma A, Satoh M, Imura N.
    Cancer Res; 1987 Feb 15; 47(4):983-7. PubMed ID: 3802104
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloroplatinum (II) against bladder tumor.
    Kondo Y, Satoh M, Imura N, Akimoto M.
    Anticancer Res; 1992 Feb 15; 12(6B):2303-7. PubMed ID: 1295477
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity to radiation treatment and changes in metallothionein synthesis in a transplanted murine tumor.
    Shibuya K, Cherian MG, Satoh M.
    Radiat Res; 1997 Sep 15; 148(3):235-9. PubMed ID: 9291354
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The effect of zinc glycyrrhizate on toxicity and anticancer activity of cisplatin in mice].
    Xu ZL, Guo JH, Song ST, Li MJ, Wu DZ.
    Yao Xue Xue Bao; 1993 Sep 15; 28(8):567-71. PubMed ID: 8285063
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Alleviation of cisplatin toxicity by high-dose bismuth subnitrate and pharmacokinetics of bismuth subnitrate and cisplatin].
    Morikawa T, Kawamura E, Komiyama T, Imura N.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun 20; 25(6):1138-45. PubMed ID: 2398299
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Protective role of metallothionein in renal toxicity of cisplatinum.
    Satoh M, Aoki Y, Tohyama C.
    Cancer Chemother Pharmacol; 1997 Jun 20; 40(4):358-62. PubMed ID: 9225956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.